2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

2:30PM-4:00PM: Abstract Number: 961

Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Psoriatic Arthritis through 3 Years: Efficacy and Safety Results from a Phase 3 Trial

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I: Psoriatic Arthritis – Treatment

2:30PM-4:00PM: Abstract Number: 986

Sex-Specific Associations Between Improvement in Gait Mechanics and Improvement in Pain, Function, and Abductor Strength after Total Hip Arthroplasty

ARHP I: Exemplary Abstracts

2:30PM-4:00PM: Abstract Number: 980

Short-Course Glucocorticoids in ANCA-Associated Vasculitis: A Proof of Concept Study

Vasculitis I: Novel Approaches to Therapy

2:30PM-4:00PM: Abstract Number: 948

Subcutaneous Abatacept in Patients with Polyarticular-Course Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety

Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Juvenile Arthritis

2:30PM-4:00PM: Abstract Number: 921

The Anti-IL-17A Antibody Secukinumab (Cosentyx®, AIN457) Diminishes the Expression of the NFκB Pathway Modulator Iκbζ

Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis I

2:30PM-4:00PM: Abstract Number: 956

The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Treatment Strategies

2:30PM-4:00PM: Abstract Number: 970

The Serotonin Receptor 2 Inhibitor Terguride Has Beneficial Effects on Skin Fibrosis: Results from a Phase 2 Proof of Concept Study

Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics I

2:30PM-4:00PM: Abstract Number: 977

Tocilizumab As an Add-on Therapy to Glucocorticoids during the First 3 Months of Treatment of Giant Cell Arteritis: Results of a French Multicenter Prospective Open-Label Study

Vasculitis I: Novel Approaches to Therapy

2:30PM-4:00PM: Abstract Number: 955

Tocilizumab Infusion Intervals Can be Extended to 5 or 6 Weeks in RA Patients Who Sustained Low Disease Activity By 4 Weeks Interval of Tocilizumab Infusion

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy I: Treatment Strategies

2:30PM-4:00PM: Abstract Number: 963

Treatment of Homocysteine Improves Urine Protein/Cr Ratio in SLE

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Nephritis

2:30PM-4:00PM: Abstract Number: 964

Tubulointerstitial Damage Is an Independent Predictor of End Stage Renal Disease in Lupus Nephritis Patients with Mild to Moderate Renal Impairment

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Nephritis

2:30PM-4:00PM: Abstract Number: 960

Ultrasonographic Improvement of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated with Ustekinumab for Chronic Plaque Psoriasis: A 52-Week, Prospective, Open Label, Controlled Cohort Study

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment I: Psoriatic Arthritis – Treatment

2:30PM-4:00PM: Abstract Number: 968

Urinary Soluble CD163, an M2 Macrophage Marker, Reflects the Renal Disease Activity in Lupus Nephritis: A Cross Sectional and Longitudinal Assessment

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Nephritis

2:30PM-4:00PM: Abstract Number: 967

Using a Hazard Index Tool Based on Short Term Renal Parameters to Predict Long Term Outcomes in Lupus Nephritis: A Novel Way to Assess New Therapies

Systemic Lupus Erythematosus – Clinical Aspects and Treatment I: Nephritis

2:30PM-4:00PM: Abstract Number: 945

When and Where Musculoskeletal Ultrasound Might Replace Magnetic Resonance in the Assessment of Patients with Juvenile Idiopathic Arthritis?

Pediatric Rheumatology – Clinical and Therapeutic Aspects I: Juvenile Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].